NK cell therapy for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your AML has come back or not responded to previous treatment
- Your leukemia cells test positive for CLL1 or CD33 marker
- You are in fairly good health (able to do daily activities) and expected to live more than 12 weeks
- You have not had a stem cell transplant before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
This early-phase study tests whether a treatment using NK cells plus monoclonal antibodies is safe and effective for adults with relapsed or hard-to-treat acute myeloid leukemia (AML). It’s mainly looking for safety, and whether the treatment can help control the leukemia.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
This trial tests a new treatment using special immune cells (called natural killer cells) made from stem cells to fight acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if these cells can safely help control or eliminate the leukemia.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests whether a special immune cell infusion (NK cells) from a half-matched family donor can help keep your AML in remission after initial chemotherapy. It is meant for people who have recently achieved their first remission and are otherwise healthy enough for a second round of chemo.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.